Schardey H M, Joosten U, Finke U, Staubach K H, Schauer R, Heiss A, Kooistra A, Rau H G, Nibler R, Lüdeling S, Unertl K, Ruckdeschel G, Exner H, Schildberg F W
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Ann Surg. 1997 Feb;225(2):172-80. doi: 10.1097/00000658-199702000-00005.
A prospective, randomized, double-blind, placebo controlled multicenter trial was undertaken in 205 patients treated with total gastrectomy for gastric malignancies to evaluate whether local antimicrobial measures reduce the incidence of esophagojejunal anastomotic leakage.
Anastomotic leakage of the esophagojejunostomy is always a septic complication of total gastrectomy for gastric malignancies, but it never has been attempted to prevent this complication with the administration of topical antimicrobial agents during the critical phase of anastomotic wound healing.
To evaluate the efficacy and safety of topical decontamination, the study was carried out as a prospective, randomized, double-blind and placebo-controlled clinical multicenter trial in patients with total gastrectomy for gastric cancer. Patients received either placebo or decontamination with polymyxin B (100 mg), tobramycin (80 mg), vancomycin (125 mg), and amphotericin B (500 mg) four times per day orally from the day before the operation until the seventh postoperative day. All patients received a perioperative intravenous prophylaxis with cefotaxime 2 x 2 g. Other interventions including the administration of antibiotics and fluids, were not affected by the study protocol.
Of 260 patients who were randomized, total gastrectomy was not carried out in 55 patients. They dropped out of the study. Patients receiving an esophagojejunostomy were observed until day 42, when they were discharged from the clinic or died. An intention-to-treat analysis of the data was carried out. Among the 103 recipients of placebo, there were 11 (10.6%) with an anastomotic leakage of the esophagojejunostomy, and among the 102 recipients of decontamination, there were 3 (2.9%) with an anastomotic leakage of the esophagojejunostomy (p = 0.0492). Pulmonary infections were observed in 23 patients (22.3%) receiving placebo and in 9 patients (8.8%) who were decontaminated (p = 0.02). There were 11 deaths (10.6%) among the recipients of placebo and 5 deaths (4.9%) among the recipients of decontamination (p = 0.1).
Decontamination with polymyxin, tobramycin, vancomycin, and amphotericin B during anastomotic wound healing is safe and effective in the prevention of esophagojejunal anastomotic leakage after total gastrectomy.
对205例因胃恶性肿瘤接受全胃切除术的患者进行了一项前瞻性、随机、双盲、安慰剂对照的多中心试验,以评估局部抗菌措施是否能降低食管空肠吻合口漏的发生率。
食管空肠吻合口漏一直是胃恶性肿瘤全胃切除术的一种感染性并发症,但在吻合口愈合的关键阶段,从未尝试通过局部应用抗菌药物来预防这种并发症。
为了评估局部去污的有效性和安全性,该研究作为一项前瞻性、随机、双盲、安慰剂对照的临床多中心试验,在因胃癌接受全胃切除术的患者中进行。患者从手术前一天至术后第七天,每天口服4次安慰剂或用多粘菌素B(100毫克)、妥布霉素(80毫克)、万古霉素(125毫克)和两性霉素B(500毫克)进行去污。所有患者围手术期静脉给予头孢噻肟2×2克进行预防。包括抗生素和液体给药在内的其他干预措施不受研究方案影响。
在随机分组的260例患者中,55例未进行全胃切除术,他们退出了研究。接受食管空肠吻合术的患者观察至第42天,此时他们出院或死亡。对数据进行意向性分析。在103例接受安慰剂的患者中,有11例(10.6%)发生食管空肠吻合口漏,在102例接受去污的患者中,有3例(2.9%)发生食管空肠吻合口漏(p = 0.0492)。接受安慰剂的23例患者(22.3%)和接受去污的9例患者(8.8%)发生肺部感染(p = 0.02)。接受安慰剂的患者中有11例死亡(10.6%),接受去污的患者中有5例死亡(4.9%)(p = 0.1)。
在吻合口愈合期间用多粘菌素、妥布霉素、万古霉素和两性霉素B进行去污在预防全胃切除术后食管空肠吻合口漏方面是安全有效的。